How Swedish Orphan Biovitrum achieved #orphandrug designation and expanded product indications #raredisease

In Uncategorized by Matt Turner

solutionDeveloping orphan drugs for rare diseases can lead to drug repositioning and uncover new indications for existing drugs or even compounds currently in development. The FDA sees the potential of increased scientific understanding as a means to reposition drugs with previously unappreciated potential to treat rare and neglected diseases. To learn more about this valuable resource for drug developers, visit The Rare Disease Repurposing Database (RDRD).


· How can rare disease research act as a portal to treat additional diseases?

· What are the possibilities as the biological understanding of disease pathways become better known?

· How can you identify the correct orphan indication during early stage development?

· What are the commercial and patient benefits to drug repositioning?

In this video, Peter Myrenfors, Director of Medical Affairs, Swedish Orphan Biovitrum discusses important scientific discoveries being made through new tools of research and how this relates to the unique challenges in rare disease research. More than just science, Dr Myrenfors stresses the importance of public-private collaborations to foster rare disease research and how through open innovation, external expertise can lead to the identification of new opportunities and new therapeutic indications for the same compounds.


There is plenty more on offer in this blog…

Discover how Prosensa is pioneering to achieve the clinical added value from their rare disease research

Feel free to leave your comments below and tell us what you want to hear at the World Orphan Drug Congress when it returns to Geneva in 2012